Along the Road to 50 States, Gustavo Mahler, Managing Partner for Dynamk Capital, speaks with Nigel about the importance of technology in cell and gene therapy.
Dr. Gustavo Mahler is a Venture Partner of Dynamk Capital LLC, having served as an Advisor to Dynamk since 2017. In 2015, Dr. Mahler became CEO of CMC Biologics, and he was a key player in the sale of CMC Biologics to the Asahi Glass Corporation in 2017. Dr. Mahler holds a Ph.D. in Biochemistry from the University of Buenos Aires, an MBA from the University of Madrid and a Leadership and Management Certification from MIT Sloan School of Management.
.svg)
